NCT05390801 Congenital Aniridia Patient Questionnaire
| NCT ID | NCT05390801 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Congenital Aniridia |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-06-08 |
| Primary Completion | 2027-12-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-06-08 with a primary completion date of 2027-12-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Congenital aniridia is a pan-ocular genetic disease characterized by a partial or complete absence of the iris, hence its name. The prevalence ranges from 1 / 40,000 to 1 / 96,000 births, but it may be underestimated. This condition combines several types of eye damage and could associate systemic manifestations, with a variable phenotype and genotype. This study aims to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease through a survey prepared by ophthalmologists from the Ophthalmology Department of Necker-Enfants Malades Hospital, reference center in France for this pathology. The patient fills it out only once.
Eligibility Criteria
Inclusion Criteria: * Any patient ≥ 18 years old with congenital aniridia and able to respond independently to the study survey, * or patients under 18 years old with congenital aniridia, whose parents can answer the study survey, * adult patients or holders of parental authority and minor patients informed and not opposed to participation in the study. Exclusion Criteria: \- Patients with neurological disorders preventing them from answering the survey, except in the case of minor patients, if the parents can answer for the patient.
Contact & Investigator
Alejandra Daruich, MD, PhD
PRINCIPAL INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT05390801 clinical trial?
This trial is open to participants of all sexes, studying Congenital Aniridia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05390801 currently recruiting?
Yes, NCT05390801 is actively recruiting participants. Contact the research team at alejandra.daruich-matet@aphp.fr for enrollment information.
Where is the NCT05390801 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT05390801 clinical trial?
NCT05390801 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Alejandra Daruich, MD, PhD at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 100 participants.